Medical Marijuana for Epilepsy and Seizures in New Jersey
Epilepsy has the strongest and most unambiguous pharmaceutical-grade evidence of any condition for which cannabis is used. Epidiolex — a purified pharmaceutical-grade CBD oral solution — received FDA approval in 2018 specifically for Dravet syndrome and Lennox-Gastaut syndrome (LGS), two severe childhood-onset epilepsies, based on multiple Phase III RCTs showing significant seizure reduction. This is not a surrogate endpoint or survey data: it is prospective, randomized, blinded evidence against placebo, in the most methodologically rigorous regulatory pathway available. Epilepsy is a direct qualifying condition for the NJ Medicinal Cannabis Program, and CBD's efficacy in seizure disorders is the clearest example of a cannabis compound doing what its mechanism predicts.
Does Epilepsy Qualify for the NJ Medicinal Cannabis Program?
Yes. Epilepsy is a direct qualifying condition. A neurologist's diagnosis is the most common documentation, but records from any licensed provider documenting an epilepsy or seizure disorder diagnosis are accepted. Patients with other seizure disorders — not just Dravet and LGS — may qualify through the epilepsy category, and the evaluation at PremierMD will assess the documentation.
Note on Epidiolex vs. NJ program cannabis: Epidiolex is a Schedule V prescription drug, the only FDA-approved cannabinoid medication for epilepsy. For patients with Dravet syndrome or LGS, the standard-of-care path is Epidiolex prescribed by a neurologist and covered by commercial insurance or Medicaid. The NJ Medicinal Cannabis Program is typically more relevant for adult epilepsy patients with seizure types not covered by Epidiolex, or for patients seeking cannabis-based adjunctive therapy alongside their existing anticonvulsant regimen. Your PremierMD provider will discuss which pathway — or both — is appropriate for your situation.
How Medical Cannabis Helps Epilepsy
CBD and Anticonvulsant Mechanisms
CBD's anticonvulsant effects occur through multiple mechanisms that are distinct from most traditional anticonvulsant medications:
- TRPV1 receptor desensitization: CBD desensitizes TRPV1 (transient receptor potential vanilloid 1) channels, which are involved in neuronal excitability and calcium-mediated seizure propagation.
- GPR55 receptor antagonism: CBD blocks GPR55, a receptor whose activation has pro-epileptic effects. GPR55 blockade may reduce neuronal excitability.
- Adenosine reuptake inhibition: CBD inhibits the cellular uptake of adenosine, elevating adenosine levels in the synaptic cleft. Adenosine has inhibitory (anti-epileptic) effects through A1 receptors.
- Sodium channel effects: CBD may also inhibit voltage-gated sodium channels, the target of many traditional anticonvulsants (valproate, carbamazepine, lamotrigine).
Importantly, CBD's anticonvulsant mechanisms are largely distinct from the sodium channel / GABA-enhancing mechanisms of most current anticonvulsants — which means CBD may have additive effects when used as an adjunct to existing anticonvulsants rather than simply duplicating their action.
THC and Seizures
The relationship between THC and seizure threshold is more complicated than CBD's. At low doses, THC may have anticonvulsant effects through CB1 receptor activation, which can reduce neuronal excitability. At higher doses, or in susceptible individuals, THC may lower seizure threshold or worsen epilepsy. For epilepsy patients, CBD-dominant products with low or no THC are the standard clinical approach. High-THC products are generally not appropriate for seizure management and may be contraindicated.
What the Research Shows
The evidence for CBD in epilepsy is the gold standard for cannabis medicine:
- Devinsky et al. (2017) — NEJM: A landmark Phase III RCT of Epidiolex (purified CBD) in 120 patients with Dravet syndrome. Convulsive seizure frequency dropped by a median of 39% in the CBD group versus 13% in placebo — a significant difference. This RCT was foundational for FDA approval.
- Thiele et al. (2018) — Lancet: A Phase III RCT of Epidiolex in 225 patients with Lennox-Gastaut syndrome. Drop seizures (the most disabling LGS seizure type) were reduced significantly with CBD versus placebo.
- Observational data in adult epilepsy: Multiple retrospective studies and patient registries in adult epilepsy patients (seizure types beyond Dravet and LGS) document seizure reduction with CBD-enriched cannabis, particularly as adjunctive therapy. Evidence is less rigorous than the pediatric RCT data but consistent in direction.
What to Bring to Your PremierMD Evaluation for Epilepsy
Bring:
- Epilepsy diagnosis records — neurologist records, EEG reports, seizure diary if available. Specify seizure type if documented (focal, generalized, myoclonic, tonic-clonic, absence, etc.).
- Your complete anticonvulsant medication list — valproate, levetiracetam, lamotrigine, clobazam, lacosamide, topiramate, carbamazepine, and others. Many anticonvulsants have significant drug interactions with CBD, particularly clobazam (CBD raises clobazam plasma levels substantially, potentially requiring dose adjustment). Your provider must review your anticonvulsant regimen before recommending cannabis.
- Notes on seizure control: how frequently do you have breakthrough seizures? What types? Are there specific triggers? What has been tried?
- If you or your child is currently on Epidiolex or has previously tried it: mention this.
Drug Interactions in Epilepsy Patients
Epilepsy patients are almost universally on anticonvulsant medications, and CBD interacts with several of them through hepatic enzyme pathways:
- Clobazam: CBD significantly inhibits CYP2C19, the enzyme that metabolizes the active metabolite of clobazam (norclobazam). This raises norclobazam levels, potentially producing both enhanced anticonvulsant effect and sedation/drowsiness. The Epidiolex trials recorded this interaction; clobazam dose adjustment is often needed when CBD is added.
- Valproate: CBD combined with valproate increases liver enzyme elevation risk. Liver function monitoring is advisable.
- Other CYP-metabolized anticonvulsants: CBD's inhibition of CYP2C19 and CYP3A4 can affect plasma levels of multiple anticonvulsants. Your provider and neurologist need to be aligned on the monitoring plan.
This interaction profile is exactly why the cannabis evaluation — where your full medication list is reviewed — is clinically important for epilepsy patients.
Insurance Coverage for Epilepsy Patients
The PremierMD evaluation is billed as a standard outpatient visit to your insurance. Epilepsy patients may be on Medicare (if disabled), Medicaid, or commercial insurance. For Epidiolex (the FDA-approved prescription CBD), insurance coverage is separate — your neurologist prescribes it, and it is covered by most plans with prior authorization.
See: Does Insurance Cover a Medical Marijuana Evaluation in NJ?
Frequently Asked Questions: Cannabis and Epilepsy in NJ
Is Epidiolex the same as medical cannabis from a dispensary?
Epidiolex is pharmaceutical-grade purified CBD in a specific oral formulation, produced under FDA pharmaceutical standards. Medical cannabis from NJ dispensaries contains CBD in varying concentrations alongside other cannabinoids. For Dravet syndrome and LGS, Epidiolex has direct RCT evidence; NJ dispensary cannabis does not have the same level of evidence for these specific conditions, though patients with other seizure types may use dispensary CBD products under physician guidance.
Will cannabis cure epilepsy?
No. Cannabis is a seizure-frequency reducer and symptom manager. It does not cure epilepsy, does not eliminate seizure risk, and should not replace properly prescribed anticonvulsant medications without neurological guidance.
My child has Dravet syndrome — is this article for us?
The strongest evidence and the FDA-approved pathway for Dravet syndrome runs through Epidiolex, prescribed by a pediatric neurologist. PremierMD evaluates adult patients. If you are a parent managing a child's epilepsy, the appropriate path begins with a pediatric epileptologist.
Should I tell my neurologist I'm using cannabis?
Yes. The drug interaction profile between CBD and anticonvulsants — particularly clobazam and valproate — means your neurologist needs to know. Cannabis is not a private addition to your epilepsy regimen; it changes the therapeutic landscape.
Get Evaluated at PremierMD
Check your eligibility or register as a patient to schedule your evaluation.
